Home » Thought Leadership

Thought Leadership

Read our insights and commentary about industry news and innovation globally. Subscribe to our monthly newsletter to keep up to date with our thought leadership, news, and updates.

Showing 5 of 8 posts
Decorative image of blog post depicting biopharma
August 25, 2020 | Blog

Ten Long-term Impacts of COVID-19 on Biopharma

COVID-19 has presented an abundance of short-term implications and challenges for biopharma companies; however, it is useful to understand and prepare for the longer-term impacts as the acute disruptions to regulatory processes and healthcare delivery begin to subside. To proactively prepare for a post-COVID-19 world, biopharma leaders should develop strategies to integrate technology across the value chain and increase focus on patient centricity in terms of process flows and treatment administration.

The 10 long term impacts of COVID-19 on biopharma from CBPartners
August 25, 2020 | Infographics

10 Long-term Impacts of COVID-19 on Biopharma

CBPartners lists the top 10 long-term trends and implications of COVID-19 on the biopharma industry as biopharma leaders prepare for a post-COVID-19 world.

CBPartners' Pharma Take-Away: AMARIN's VASCEPA patent loss: is it obvious(ness)?
May 26, 2020 | Podcasts

COVID-19 (Pt 3): Testing

The final episode of the COVID-19 trilogy focuses on testing. Specifically, the different types of tests available for COVID-19 and the regulatory environment in which these tests exist.

April 30, 2020 | Culture Blog, News

cbpGIVES Raises $4,150 Within the Firm to Support COVID-19 Relief Efforts

The global COVID-19 crisis has affected many individuals worldwide in substantial ways, including increasing food insecurity, medical burden and economic loss. CBPartners' charitable faction cbpGIVES coordinated efforts firm-wide to raise funds to support COVID-19 relief. CBPartners has matched every dollar raised by employees and have raised a total of $4,150 to donate to several organizations across the world.

covid trial disruptions
April 29, 2020 | Blog

Clinical Trial Disruptions: Can Small-Cap Biopharma Companies Weather the Impact of COVID-19?

Cumulative costs from patient enrollment scenarios due to COVID-19 will likely generate a significant financial drain on biopharma R&D expenditures. CBPartners' blog post investigates this impact and explores mitigation strategies.